Is Synopsys (SNPS) a risky stock?
As of July 21, 2026, Clavix grades Synopsys (SNPS) C for risk, a composite score of 56 out of 100 on an A+ to F scale, which puts SNPS in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind SNPS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how SNPS scores on each, as of July 21, 2026.
What's moving SNPS's risk right now
Company-specific signals Clavix flags behind SNPS's current grade, drawn from recent news and filings as of July 21, 2026.
In Q1, Harel Insurance nearly exited its Synopsys stake, SEB Asset Management opened a new position, and Illinois Municipal Retirement Fund trimmed its holding by 19.9%. None of these were large enough to move the stock.
Synopsys benefits from customers being locked into its chip design tools and tight ties with chip foundries, which supports premium pricing on long contracts. But large customers still have enough leverage to negotiate material discounts.
SNPS has dropped back to $417, a price floor it has held six times before. Whether that support holds again or finally breaks is the key question for the stock now.
What a C grade means
On the Clavix A+ to F scale, SNPS's composite of 56 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell SNPS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.